Analyst initiated coverage on Omada Health with a new price target
$OMDA
Medical/Nursing Services
Health Care
Analyst initiated coverage of Omada Health with a rating of Overweight and set a new price target of $19.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/1/2025 | $21.00 | Outperform | Evercore ISI |
| 7/1/2025 | $25.00 | Overweight | Morgan Stanley |
| 7/1/2025 | $19.00 | Overweight | Analyst |
| 7/1/2025 | $23.00 | Buy | Needham |
| 7/1/2025 | $21.00 | Overweight | Barclays |
| 7/1/2025 | $29.00 | Buy | Goldman |
| 7/1/2025 | $27.00 | Buy | Canaccord Genuity |
SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)
8-K - Omada Health, Inc. (0001611115) (Filer)
424B4 - Omada Health, Inc. (0001611115) (Filer)
Evercore ISI initiated coverage of Omada Health with a rating of Outperform and set a new price target of $21.00
Morgan Stanley initiated coverage of Omada Health with a rating of Overweight and set a new price target of $25.00
Analyst initiated coverage of Omada Health with a rating of Overweight and set a new price target of $19.00
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thursday, August 7, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e. A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same l
SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in
Issued on behalf of Avant Technologies Inc.Equity Insider News Commentary VANCOUVER, BC, June 10, 2025 /PRNewswire/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speeches from former British Prime Minister Tony Blair, who insists that the UK needs to embrace a future with AI doctors and nurses, or risk being left behind. A new report from Wolters Kluwer has experts calling for more clarity around its use, adoption, and business strategy, because most healthcare organizations aren't currently ready to use GenAI too
SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thursday, August 7, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e. A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same l
SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in